Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	insulin receptor activity	INSR INSRR	2.31e-05	3	56	2	GO:0005009
GeneOntologyMolecularFunction	serine-type endopeptidase activity	HGFAC RHBDF1 LPA PLG OVCH1	1.91e-04	190	56	5	GO:0004252
GeneOntologyMolecularFunction	serine-type peptidase activity	HGFAC RHBDF1 LPA PLG OVCH1	2.84e-04	207	56	5	GO:0008236
GeneOntologyMolecularFunction	serine hydrolase activity	HGFAC RHBDF1 LPA PLG OVCH1	3.17e-04	212	56	5	GO:0017171
GeneOntologyMolecularFunction	phosphatidate phosphatase activity	LPIN3 LPIN2	6.88e-04	14	56	2	GO:0008195
GeneOntologyMolecularFunction	insulin receptor substrate binding	INSR INSRR	7.92e-04	15	56	2	GO:0043560
GeneOntologyMolecularFunction	protein antigen binding	LPA PLG	9.04e-04	16	56	2	GO:1990405
GeneOntologyMolecularFunction	low-density lipoprotein particle receptor activity	LRP10 LRP1B	9.04e-04	16	56	2	GO:0005041
GeneOntologyMolecularFunction	lipid phosphatase activity	LPIN3 LPIN2	1.28e-03	19	56	2	GO:0042577
GeneOntologyMolecularFunction	apolipoprotein binding	LPA PLG	1.42e-03	20	56	2	GO:0034185
GeneOntologyMolecularFunction	lipoprotein particle receptor activity	LRP10 LRP1B	1.57e-03	21	56	2	GO:0030228
GeneOntologyMolecularFunction	protein-hormone receptor activity	INSR INSRR	1.72e-03	22	56	2	GO:0016500
GeneOntologyMolecularFunction	cargo receptor activity	LRP10 INSR LRP1B	1.75e-03	85	56	3	GO:0038024
GeneOntologyMolecularFunction	extracellular matrix structural constituent	TINAGL1 LAMC1 MUC2 MUC6	1.91e-03	188	56	4	GO:0005201
GeneOntologyCellularComponent	insulin receptor complex	INSR INSRR	4.37e-05	4	57	2	GO:0005899
GeneOntologyCellularComponent	extracellular matrix	TINAGL1 CRISPLD2 LPA LAMC1 PLG MUC2 MUC6 OTOG	3.83e-04	656	57	8	GO:0031012
GeneOntologyCellularComponent	external encapsulating structure	TINAGL1 CRISPLD2 LPA LAMC1 PLG MUC2 MUC6 OTOG	3.91e-04	658	57	8	GO:0030312
MousePheno	abnormal mammary gland connective tissue morphology	LPA PLG	7.98e-06	2	40	2	MP:0009507
MousePheno	esophageal ulcer	LPA PLG	7.98e-06	2	40	2	MP:0004547
MousePheno	duodenal ulcer	LPA PLG	7.98e-06	2	40	2	MP:0003273
MousePheno	perianal ulcer	LPA PLG	7.98e-06	2	40	2	MP:0005035
MousePheno	ectropion	LPA PLG	7.98e-06	2	40	2	MP:0006164
MousePheno	absent cornea epithelium	LPA PLG	2.39e-05	3	40	2	MP:0020856
MousePheno	increased circulating fibrinogen level	LPA PLG	4.77e-05	4	40	2	MP:0012331
MousePheno	proctitis	LPA PLG	4.77e-05	4	40	2	MP:0003305
MousePheno	gastric ulcer	LPA PLG	1.19e-04	6	40	2	MP:0003282
MousePheno	increased acute phase protein level	LPA PLG	1.66e-04	7	40	2	MP:0014499
MousePheno	abnormal conjunctival epithelium morphology	LPA PLG	1.66e-04	7	40	2	MP:0004481
MousePheno	venoocclusion	LPA PLG	1.66e-04	7	40	2	MP:0006137
MousePheno	peptic ulcer	LPA PLG	1.66e-04	7	40	2	MP:0003301
MousePheno	decreased keratinocyte migration	LPA PLG	2.21e-04	8	40	2	MP:0012194
MousePheno	abnormal circulating fibrinogen level	LPA PLG	2.21e-04	8	40	2	MP:0010213
MousePheno	decreased susceptibility to induced morbidity/mortality	LPA INSR NOX4 PLG	2.31e-04	106	40	4	MP:0009764
MousePheno	abnormal Cajal-Retzius cell morphology	FKRP LAMC1	3.54e-04	10	40	2	MP:0008030
MousePheno	decreased susceptibility to induced choroidal neovascularization	LPA PLG	3.54e-04	10	40	2	MP:0003434
MousePheno	abnormal kidney thrombosis	LPA PLG	3.54e-04	10	40	2	MP:0011507
MousePheno	abnormal keratinocyte migration	LPA PLG	4.32e-04	11	40	2	MP:0012192
MousePheno	abnormal meninges morphology	FKRP LAMC1	5.17e-04	12	40	2	MP:0005623
MousePheno	enlarged lymph nodes	PHF20L1 LPA CNGB3 LPIN2 NOX4 ALOXE3 PLG	5.22e-04	507	40	7	MP:0000702
MousePheno	abnormal anus morphology	LPA PLG	6.10e-04	13	40	2	MP:0005034
MousePheno	abnormal conjunctiva morphology	LPA PLG	6.10e-04	13	40	2	MP:0001310
MousePheno	decreased cell migration	MYO9A LPA PLG	8.38e-04	65	40	3	MP:0011805
MousePheno	abnormal lymph node size	PHF20L1 LPA CNGB3 LPIN2 NOX4 ALOXE3 PLG	9.50e-04	561	40	7	MP:0000701
MousePheno	increased hepatocyte proliferation	LPA PLG	1.06e-03	17	40	2	MP:0003893
MousePheno	lactation failure	LPA PLG	1.06e-03	17	40	2	MP:0010249
MousePheno	decreased neuron apoptosis	LPA NOX4 PLG	1.18e-03	73	40	3	MP:0003204
MousePheno	choroidal neovascularization	LPA PLG	1.32e-03	19	40	2	MP:0005546
MousePheno	abnormal cortical marginal zone morphology	FKRP LAMC1	1.32e-03	19	40	2	MP:0000792
MousePheno	abnormal Muller cell morphology	FKRP CRB1	1.47e-03	20	40	2	MP:0005547
MousePheno	increased urine microalbumin level	SCAMP5 MAS1	1.47e-03	20	40	2	MP:0002959
Domain	VWD	SUSD2 MUC2 MUC6 OTOG	1.19e-07	16	55	4	SM00216
Domain	VWF_type-D	SUSD2 MUC2 MUC6 OTOG	1.19e-07	16	55	4	IPR001846
Domain	VWFD	SUSD2 MUC2 MUC6 OTOG	1.19e-07	16	55	4	PS51233
Domain	VWD	SUSD2 MUC2 MUC6 OTOG	1.19e-07	16	55	4	PF00094
Domain	SCAMP	SCAMP5 SCAMP1 SCAMP2	2.41e-07	5	55	3	IPR007273
Domain	SCAMP	SCAMP5 SCAMP1 SCAMP2	2.41e-07	5	55	3	PF04144
Domain	TIL	MUC2 MUC6 OTOG	5.22e-06	12	55	3	PF01826
Domain	C8	MUC2 MUC6 OTOG	5.22e-06	12	55	3	PF08742
Domain	Unchr_dom_Cys-rich	MUC2 MUC6 OTOG	6.77e-06	13	55	3	IPR014853
Domain	C8	MUC2 MUC6 OTOG	6.77e-06	13	55	3	SM00832
Domain	TIL_dom	MUC2 MUC6 OTOG	8.60e-06	14	55	3	IPR002919
Domain	Kringle	HGFAC LPA PLG	1.60e-05	17	55	3	IPR000001
Domain	Kringle_CS	HGFAC LPA PLG	1.60e-05	17	55	3	IPR018056
Domain	KRINGLE_2	HGFAC LPA PLG	1.60e-05	17	55	3	PS50070
Domain	Kringle	HGFAC LPA PLG	1.60e-05	17	55	3	PF00051
Domain	KRINGLE_1	HGFAC LPA PLG	1.60e-05	17	55	3	PS00021
Domain	KR	HGFAC LPA PLG	1.60e-05	17	55	3	SM00130
Domain	VWC_out	MUC2 MUC6 OTOG	2.26e-05	19	55	3	SM00215
Domain	Lipin_N	LPIN3 LPIN2	2.55e-05	3	55	2	IPR007651
Domain	Lipin_mid	LPIN3 LPIN2	2.55e-05	3	55	2	PF16876
Domain	Tyr_kinase_insulin-like_rcpt	INSR INSRR	2.55e-05	3	55	2	IPR016246
Domain	Lipin_mid	LPIN3 LPIN2	2.55e-05	3	55	2	IPR031703
Domain	Lipin_N	LPIN3 LPIN2	2.55e-05	3	55	2	PF04571
Domain	CT	MUC2 MUC6 OTOG	3.58e-05	22	55	3	SM00041
Domain	Cys_knot_C	MUC2 MUC6 OTOG	5.31e-05	25	55	3	IPR006207
Domain	CTCK_2	MUC2 MUC6 OTOG	5.31e-05	25	55	3	PS01225
Domain	Growth_fac_rcpt_	INSR INSRR LAMC1 LRP1B CRB1	9.47e-05	156	55	5	IPR009030
Domain	Kringle-like	HGFAC LPA PLG	1.13e-04	32	55	3	IPR013806
Domain	LNS2	LPIN3 LPIN2	1.27e-04	6	55	2	PF08235
Domain	LNS2	LPIN3 LPIN2	1.27e-04	6	55	2	IPR013209
Domain	LNS2	LPIN3 LPIN2	1.27e-04	6	55	2	SM00775
Domain	LNS2/PITP	LPIN3 LPIN2	1.27e-04	6	55	2	IPR031315
Domain	Furin-like	INSR INSRR	1.77e-04	7	55	2	PF00757
Domain	Rcpt_L-dom	INSR INSRR	1.77e-04	7	55	2	IPR000494
Domain	Furin-like_Cys-rich_dom	INSR INSRR	1.77e-04	7	55	2	IPR006211
Domain	Recep_L_domain	INSR INSRR	1.77e-04	7	55	2	PF01030
Domain	-	INSR INSRR	1.77e-04	7	55	2	3.80.20.20
Domain	TRYPSIN_HIS	HGFAC LPA PLG OVCH1	2.40e-04	103	55	4	IPR018114
Domain	VWF_dom	MUC2 MUC6 OTOG	2.56e-04	42	55	3	IPR001007
Domain	TRYPSIN_SER	HGFAC LPA PLG OVCH1	2.68e-04	106	55	4	PS00135
Domain	TRYPSIN_HIS	HGFAC LPA PLG OVCH1	2.77e-04	107	55	4	PS00134
Domain	SO	TINAGL1 SUSD2	3.02e-04	9	55	2	SM00201
Domain	Peptidase_S1A	HGFAC LPA PLG OVCH1	3.42e-04	113	55	4	IPR001314
Domain	TRYPSIN_DOM	HGFAC LPA PLG OVCH1	3.65e-04	115	55	4	PS50240
Domain	Somatomedin_B_dom	TINAGL1 SUSD2	3.77e-04	10	55	2	IPR001212
Domain	SMB_1	TINAGL1 SUSD2	3.77e-04	10	55	2	PS00524
Domain	SMB_2	TINAGL1 SUSD2	3.77e-04	10	55	2	PS50958
Domain	Tryp_SPc	HGFAC LPA PLG OVCH1	3.90e-04	117	55	4	SM00020
Domain	CUB	LRP10 CDCP2 OVCH1	4.04e-04	49	55	3	PF00431
Domain	CUB	LRP10 CDCP2 OVCH1	4.29e-04	50	55	3	SM00042
Domain	Trypsin	HGFAC LPA PLG OVCH1	4.43e-04	121	55	4	PF00089
Domain	Trypsin_dom	HGFAC LPA PLG OVCH1	4.43e-04	121	55	4	IPR001254
Domain	Tyr_kinase_rcpt_2_CS	INSR INSRR	4.60e-04	11	55	2	IPR002011
Domain	Peptidase_S1_PA	HGFAC LPA PLG OVCH1	4.71e-04	123	55	4	IPR009003
Domain	-	LRP10 CDCP2 OVCH1	4.82e-04	52	55	3	2.60.120.290
Domain	CUB	LRP10 CDCP2 OVCH1	5.10e-04	53	55	3	PS01180
Domain	RECEPTOR_TYR_KIN_II	INSR INSRR	5.51e-04	12	55	2	PS00239
Domain	EGF_3	HGFAC TMEM8B LRP1B CRB1 OTOG	6.30e-04	235	55	5	PS50026
Domain	EGF	HGFAC TMEM8B LAMC1 LRP1B CRB1	6.30e-04	235	55	5	SM00181
Domain	CUB_dom	LRP10 CDCP2 OVCH1	6.32e-04	57	55	3	IPR000859
Domain	EGF-like_dom	HGFAC LAMC1 LRP1B CRB1 OTOG	8.17e-04	249	55	5	IPR000742
Domain	EGF_1	HGFAC TMEM8B LAMC1 LRP1B CRB1	9.09e-04	255	55	5	PS00022
Domain	EGF-like_CS	HGFAC TMEM8B LAMC1 LRP1B CRB1	1.01e-03	261	55	5	IPR013032
Domain	EGF_2	HGFAC TMEM8B LAMC1 LRP1B CRB1	1.08e-03	265	55	5	PS01186
Domain	Furin_repeat	INSR INSRR	1.26e-03	18	55	2	IPR006212
Domain	FU	INSR INSRR	1.26e-03	18	55	2	SM00261
Domain	TRYPSIN_SER	HGFAC PLG OVCH1	2.37e-03	90	55	3	IPR033116
Pathway	REACTOME_SYNTHESIS_OF_PE	LPIN3 LPIN2	4.35e-04	12	37	2	MM14586
Pathway	REACTOME_TRIGLYCERIDE_BIOSYNTHESIS	LPIN3 LPIN2	4.35e-04	12	37	2	MM15447
Pathway	REACTOME_DEPOLYMERIZATION_OF_THE_NUCLEAR_LAMINA	LPIN3 LPIN2	4.35e-04	12	37	2	MM15105
Pathway	BIOCARTA_FIBRINOLYSIS_PATHWAY	LPA PLG	4.35e-04	12	37	2	MM1398
Pathway	REACTOME_SYNTHESIS_OF_PE	LPIN3 LPIN2	5.13e-04	13	37	2	M656
Pathway	BIOCARTA_PLATELETAPP_PATHWAY	LPA PLG	5.98e-04	14	37	2	MM1458
Pathway	REACTOME_TRIGLYCERIDE_BIOSYNTHESIS	LPIN3 LPIN2	5.98e-04	14	37	2	M619
Pathway	REACTOME_DEPOLYMERIZATION_OF_THE_NUCLEAR_LAMINA	LPIN3 LPIN2	6.89e-04	15	37	2	M27360
Pathway	REACTOME_DISSOLUTION_OF_FIBRIN_CLOT	LPA PLG	6.89e-04	15	37	2	MM15450
Pathway	WP_BDNF_PATHWAY	LPA PLG	7.86e-04	16	37	2	MM15816
Pathway	WP_CONGENITAL_GENERALIZED_LIPODYSTROPHY	LPIN3 LPIN2	9.99e-04	18	37	2	M42546
Pathway	WP_ETHER_LIPID_BIOSYNTHESIS	LPIN3 LPIN2	1.24e-03	20	37	2	M46451
Pathway	REACTOME_TERMINATION_OF_O_GLYCAN_BIOSYNTHESIS	MUC2 MUC6	1.36e-03	21	37	2	MM15706
Pathway	WP_NANOPARTICLE_TRIGGERED_AUTOPHAGIC_CELL_DEATH	ATG7 INSR	1.64e-03	23	37	2	M39325
Pathway	REACTOME_TRIGLYCERIDE_METABOLISM	LPIN3 LPIN2	1.64e-03	23	37	2	MM15575
Pathway	WP_BLOOD_CLOTTING_CASCADE	LPA PLG	1.64e-03	23	37	2	MM15936
Pubmed	Secretory carrier membrane proteins interact and regulate trafficking of the organellar (Na+,K+)/H+ exchanger NHE7.	SCAMP5 SCAMP1 SCAMP2	1.67e-08	4	57	3	15840657
Pubmed	Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes.	LPA PLG LPAL2	1.67e-08	4	57	3	21900290
Pubmed	Novel SCAMPs lacking NPF repeats: ubiquitous and synaptic vesicle-specific forms implicate SCAMPs in multiple membrane-trafficking functions.	SCAMP5 SCAMP1 SCAMP2	4.16e-08	5	57	3	11050114
Pubmed	Localization of the Mas proto-oncogene to a densely marked region of mouse chromosome 17 associated with genomic imprinting.	MAS1 LPA PLG	4.16e-08	5	57	3	1612602
Pubmed	Bidirectional action of the Igf2r imprint control element on upstream and downstream imprinted genes.	MAS1 LPA PLG	2.32e-07	8	57	3	11562346
Pubmed	High-resolution genetic analysis of a deletion on mouse chromosome 17 extending over the fused, tufted, and homeobox Nkx2-5 loci.	MAS1 LPA PLG	2.32e-07	8	57	3	7894168
Pubmed	Long-range DNase I hypersensitivity mapping reveals the imprinted Igf2r and Air promoters share cis-regulatory elements.	MAS1 LPA PLG	2.32e-07	8	57	3	16204191
Pubmed	Tissue-specific regulation of Igf2r/Airn imprinting during gastrulation.	MAS1 LPA PLG	3.48e-07	9	57	3	25918552
Pubmed	Characterization of the C3 YAC contig from proximal mouse chromosome 17 and analysis of allelic expression of genes flanking the imprinted Igf2r gene.	MAS1 LPA PLG	6.82e-07	11	57	3	9268631
Pubmed	Genetic analysis of the organic cation transporter genes Orct2/Slc22a2 and Orct3/Slc22a3 reduces the critical region for the t haplotype mutant t(w73) to 200 kb.	MAS1 LPA PLG	1.50e-06	14	57	3	11641723
Pubmed	Quantitative trait loci analysis reveals candidate genes implicated in regulating functional deficit and CNS vascular permeability in CD8 T cell-initiated blood-brain barrier disruption.	MAS1 LPA PLG	1.87e-06	15	57	3	24090483
Pubmed	Short-term inhibition of fibrinolytic system restores locomotor function after spinal cord injury in mice.	LPA PLG	2.64e-06	2	57	2	31690812
Pubmed	Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer's disease.	LPA PLG	2.64e-06	2	57	2	30254165
Pubmed	Characterization of a hybrid receptor formed by dimerization of the insulin receptor-related receptor (IRR) with the insulin receptor (IR): coexpression of cDNAs encoding human IRR and human IR in NIH-3T3 cells.	INSR INSRR	2.64e-06	2	57	2	8916919
Pubmed	Plasminogen deficiency exacerbates skeletal muscle loss during mechanical unloading in developing mice.	LPA PLG	2.64e-06	2	57	2	38328826
Pubmed	Reduced transplant arteriosclerosis in plasminogen-deficient mice.	LPA PLG	2.64e-06	2	57	2	9819364
Pubmed	Persistent corneal haze after excimer laser photokeratectomy in plasminogen-deficient mice.	LPA PLG	2.64e-06	2	57	2	10634603
Pubmed	Thrombomodulin functions as a plasminogen receptor to modulate angiogenesis.	LPA PLG	2.64e-06	2	57	2	23943648
Pubmed	In vivo plasminogen deficiency reduces fat accumulation.	LPA PLG	2.64e-06	2	57	2	12083480
Pubmed	Polymorphonuclear leukocyte phagocytic function increases in plasminogen knockout mice.	LPA PLG	2.64e-06	2	57	2	18420257
Pubmed	Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction.	LPA PLG	2.64e-06	2	57	2	7705657
Pubmed	Nucleocytoplasmic coagulation: an injury-induced aggregation event that disulfide crosslinks proteins and facilitates their removal by plasmin.	LPA PLG	2.64e-06	2	57	2	23041318
Pubmed	Plasminogen alleles influence susceptibility to invasive aspergillosis.	LPA PLG	2.64e-06	2	57	2	18566672
Pubmed	A novel role for plasmin-mediated degradation of opsonizing antibody in the evasion of host immunity by virulent, but not attenuated, Francisella tularensis.	LPA PLG	2.64e-06	2	57	2	19752236
Pubmed	Plasminogen Tochigi: inactive plasmin resulting from replacement of alanine-600 by threonine in the active site.	LPA PLG	2.64e-06	2	57	2	6216475
Pubmed	The generation and characterization of mice expressing a plasmin-inactivating active site mutation.	LPA PLG	2.64e-06	2	57	2	20653841
Pubmed	Influence of plasminogen deficiency on the contribution of polymorphonuclear leucocytes to fibrin/ogenolysis: studies in plasminogen knock-out mice.	LPA PLG	2.64e-06	2	57	2	12428098
Pubmed	Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus.	LPA PLG	2.64e-06	2	57	2	20440070
Pubmed	Plasminogen deficiency causes reduced corticospinal axonal plasticity and functional recovery after stroke in mice.	LPA PLG	2.64e-06	2	57	2	24732409
Pubmed	SCAMP2/5 as diagnostic and prognostic markers for acute myeloid leukemia.	SCAMP5 SCAMP2	2.64e-06	2	57	2	34426610
Pubmed	A central role for plasminogen in the inflammatory response to biomaterials.	LPA PLG	2.64e-06	2	57	2	15456492
Pubmed	Plasminogen promotes macrophage phagocytosis in mice.	LPA PLG	2.64e-06	2	57	2	24876560
Pubmed	Plasminogen is a joint-specific positive or negative determinant of arthritis pathogenesis in mice.	LPA PLG	2.64e-06	2	57	2	24574269
Pubmed	Spontaneous development of otitis media in plasminogen-deficient mice.	LPA PLG	2.64e-06	2	57	2	16956791
Pubmed	Staphylococcus aureus manganese transport protein C (MntC) is an extracellular matrix- and plasminogen-binding protein.	LPA PLG	2.64e-06	2	57	2	25409527
Pubmed	The mouse plasminogen locus maps to the recombination breakpoints of the tLub2 and TtOrl partial t haplotypes but is not at the tw73 locus.	LPA PLG	2.64e-06	2	57	2	1543918
Pubmed	Restoration of thrombolytic potential in plasminogen-deficient mice by bolus administration of plasminogen.	LPA PLG	2.64e-06	2	57	2	8704243
Pubmed	Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals.	LPA PLG	2.64e-06	2	57	2	17267741
Pubmed	Plasmin promotes foam cell formation by increasing macrophage catabolism of aggregated low-density lipoprotein.	LPA PLG	2.64e-06	2	57	2	23702659
Pubmed	Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen on the surface of vascular endothelial and smooth muscle cells.	LPA PLG	2.64e-06	2	57	2	29990619
Pubmed	Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector.	LPA PLG	2.64e-06	2	57	2	17293777
Pubmed	Role of secretory carrier membrane protein SCAMP2 in granule exocytosis.	SCAMP1 SCAMP2	2.64e-06	2	57	2	12475951
Pubmed	Preserved pancreatic beta-cell development and function in mice lacking the insulin receptor-related receptor.	INSR INSRR	2.64e-06	2	57	2	11463843
Pubmed	Plasminogen plays a crucial role in bone repair.	LPA PLG	2.64e-06	2	57	2	23456978
Pubmed	Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction.	LPA PLG	2.64e-06	2	57	2	10854210
Pubmed	Gender affects skin wound healing in plasminogen deficient mice.	LPA PLG	2.64e-06	2	57	2	23527289
Pubmed	Dengue virus-induced autoantibodies bind to plasminogen and enhance its activation.	LPA PLG	2.64e-06	2	57	2	22079981
Pubmed	Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice.	LPA PLG	2.64e-06	2	57	2	9490683
Pubmed	The central exons of the human MUC2 and MUC6 mucins are highly repetitive and variable in sequence between individuals.	MUC2 MUC6	2.64e-06	2	57	2	30504806
Pubmed	Kringle 5 of human plasminogen suppresses hepatocellular carcinoma growth both in grafted and xenografted mice by anti-angiogenic activity.	LPA PLG	2.64e-06	2	57	2	16481742
Pubmed	Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation.	LPA PLG	2.64e-06	2	57	2	18983515
Pubmed	Plasminogen Regulates Fracture Repair by Promoting the Functions of Periosteal Mesenchymal Progenitors.	LPA PLG	2.64e-06	2	57	2	34378815
Pubmed	Plasmin generation plays different roles in the formation and removal of arterial and venous thrombus in mice.	LPA PLG	2.64e-06	2	57	2	11848464
Pubmed	Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice.	LPA PLG	2.64e-06	2	57	2	7586361
Pubmed	Plasminogen/plasmin modulates bone metabolism by regulating the osteoblast and osteoclast function.	LPA PLG	2.64e-06	2	57	2	21239499
Pubmed	Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.	LPA PLG	2.64e-06	2	57	2	10642175
Pubmed	Plasminogen mRNA induction in the mouse brain after kainate excitation: codistribution with plasminogen activator inhibitor-2 (PAI-2) mRNA.	LPA PLG	2.64e-06	2	57	2	12225871
Pubmed	Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice.	LPA PLG	2.64e-06	2	57	2	9770530
Pubmed	Plasminogen activation is required for the development of radiation-induced dermatitis.	LPA PLG	2.64e-06	2	57	2	30323258
Pubmed	Plasminogen deficiency suppresses pancreatic ductal adenocarcinoma disease progression.	LPA PLG	2.64e-06	2	57	2	37971174
Pubmed	The plasminogen activation system enhances brain and heart invasion in murine relapsing fever borreliosis.	LPA PLG	2.64e-06	2	57	2	9884337
Pubmed	Colonic Lesions, Cytokine Profiles, and Gut Microbiota in Plasminogen-Deficient Mice.	LPA PLG	2.64e-06	2	57	2	26473342
Pubmed	The complete genomic organization of the human MUC6 and MUC2 mucin genes.	MUC2 MUC6	2.64e-06	2	57	2	15081123
Pubmed	Nonfibrinolytic functions of plasminogen.	LPA PLG	2.64e-06	2	57	2	10816371
Pubmed	High-fat Diet Alters the Glycosylation Patterns of Duodenal Mucins in a Murine Model.	MUC2 MUC6	2.64e-06	2	57	2	32141795
Pubmed	MUC2 and MUC6 apomucins expression in human gastric neoplasm: an immunohistochemical analysis.	MUC2 MUC6	2.64e-06	2	57	2	20878553
Pubmed	Plasminogen is a critical regulator of cutaneous wound healing.	LPA PLG	2.64e-06	2	57	2	26791370
Pubmed	Selection of mutant µplasmin for amyloid-β cleavage in vivo.	LPA PLG	2.64e-06	2	57	2	32694536
Pubmed	Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.	LPA PLG	2.64e-06	2	57	2	7525077
Pubmed	Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models.	LPA PLG	2.64e-06	2	57	2	16052596
Pubmed	Functional corpora lutea are formed in matrix metalloproteinase inhibitor-treated plasminogen-deficient mice.	LPA PLG	2.64e-06	2	57	2	17122079
Pubmed	Role of plasminogen in propagation of scrapie.	LPA PLG	2.64e-06	2	57	2	16103174
Pubmed	Differential expression of oxidized/native lipoprotein(a) and plasminogen in human carotid and cerebral artery plaques.	LPA PLG	2.64e-06	2	57	2	21300353
Pubmed	Beta-amyloid (Abeta) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation.	LPA PLG	2.64e-06	2	57	2	15737740
Pubmed	Selective behaviors altered in plasminogen-deficient mice are reconstituted with intracerebroventricular injection of plasminogen.	LPA PLG	2.64e-06	2	57	2	11306011
Pubmed	Localization of regulatory elements mediating constitutive and cytokine-stimulated plasminogen gene expression.	LPA PLG	2.64e-06	2	57	2	12149246
Pubmed	Plasminogen deficiency attenuates postnatal erythropoiesis in male C57BL/6 mice through decreased activity of the LH-testosterone axis.	LPA PLG	2.64e-06	2	57	2	22056679
Pubmed	Protective effects of plasmin(ogen) in a mouse model of Staphylococcus aureus-induced arthritis.	LPA PLG	2.64e-06	2	57	2	18311818
Pubmed	Localization of plasminogen in mouse hippocampus, cerebral cortex, and hypothalamus.	LPA PLG	2.64e-06	2	57	2	21190118
Pubmed	The lack of binding of VEK-30, an internal peptide from the group A streptococcal M-like protein, PAM, to murine plasminogen is due to two amino acid replacements in the plasminogen kringle-2 domain.	LPA PLG	2.64e-06	2	57	2	18039665
Pubmed	Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice.	LPA PLG	2.64e-06	2	57	2	9671388
Pubmed	A physiological function for apolipoprotein(a): a natural regulator of the inflammatory response.	LPA PLG	2.64e-06	2	57	2	18997104
Pubmed	Growth and behavioral development in plasminogen gene-targeted mice.	LPA PLG	2.64e-06	2	57	2	10885855
Pubmed	Cellular density regulation of plasminogen gene expression in mouse hepatocytes.	LPA PLG	2.64e-06	2	57	2	12559391
Pubmed	Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.	LPA PLG	2.64e-06	2	57	2	27319402
Pubmed	Plasminogen is a critical host pathogenicity factor for group A streptococcal infection.	LPA PLG	2.64e-06	2	57	2	15333838
Pubmed	Apo(a) promotes thrombosis in a vascular injury model by a mechanism independent of plasminogen.	LPA PLG	2.64e-06	2	57	2	16150044
Pubmed	Plasminogen has a broad extrahepatic distribution.	LPA PLG	2.64e-06	2	57	2	11916082
Pubmed	Unaltered prion protein cleavage in plasminogen-deficient mice.	LPA PLG	2.64e-06	2	57	2	16543819
Pubmed	Essential role of DNA-PKcs and plasminogen for the development of doxorubicin-induced glomerular injury in mice.	LPA PLG	2.64e-06	2	57	2	34423816
Pubmed	Delayed invasion of the kidney and brain by Borrelia crocidurae in plasminogen-deficient mice.	LPA PLG	2.64e-06	2	57	2	11500461
Pubmed	Growth of human squamous cell carcinoma xenografts in mice is inhibited by local angiostatin gene therapy.	LPA PLG	2.64e-06	2	57	2	12167431
Pubmed	Impaired wound healing in mice with a disrupted plasminogen gene.	LPA PLG	2.64e-06	2	57	2	8612226
Pubmed	Role of plasminogen activation in neuronal organization and survival.	LPA PLG	2.64e-06	2	57	2	19683575
Pubmed	Ovulation in plasminogen-deficient mice.	LPA PLG	2.64e-06	2	57	2	10537128
Pubmed	Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis.	LPA PLG	2.64e-06	2	57	2	23555246
Pubmed	Binding of plasminogen to hepatocytes isolated from injured mouse liver and nonparenchymal-cell-dependent proliferation of hepatocytes.	LPA PLG	2.64e-06	2	57	2	18685433
Pubmed	Plasminogen mediates communication between the peripheral and central immune systems during systemic immune challenge with lipopolysaccharide.	LPA PLG	2.64e-06	2	57	2	31462325
Pubmed	Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis.	LPA PLG	2.64e-06	2	57	2	9242524
Pubmed	Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice.	LPA PLG	7.91e-06	3	57	2	16818777
Interaction	SLC9A7 interactions	SCAMP5 SCAMP1 SCAMP2	4.39e-06	12	56	3	int:SLC9A7
Cytoband	Ensembl 112 genes in cytogenetic band chr6q26	LPA PLG	1.80e-04	16	57	2	chr6q26
Cytoband	6q26	LPA PLG	2.29e-04	18	57	2	6q26
Cytoband	Ensembl 112 genes in cytogenetic band chr14q23	TMEM30B FNTB JKAMP	5.80e-04	130	57	3	chr14q23
Cytoband	14q23.1	TMEM30B JKAMP	1.58e-03	47	57	2	14q23.1
Cytoband	7p22.1	RSPH10B2 RSPH10B	1.58e-03	47	57	2	7p22.1
Cytoband	9p13.3	TMEM8B SPAG8	3.97e-03	75	57	2	9p13.3
GeneFamily	Secretory carrier membrane proteins	SCAMP5 SCAMP1 SCAMP2	4.11e-08	5	30	3	735
GeneFamily	Lipins	LPIN3 LPIN2	7.98e-06	3	30	2	1043
GeneFamily	Low density lipoprotein receptors	LRP10 LRP1B	2.05e-04	13	30	2	634
GeneFamily	CD molecules\|Mucins	MUC2 MUC6	5.48e-04	21	30	2	648
GeneFamily	Receptor Tyrosine Kinases\|CD molecules	INSR INSRR	2.00e-03	40	30	2	321
GeneFamily	PHD finger proteins	ING3 PHF20L1	9.74e-03	90	30	2	88
GeneFamily	Fibronectin type III domain containing	INSR INSRR	2.88e-02	160	30	2	555
Coexpression	PILON_KLF1_TARGETS_UP	ABCC3 HGFAC RHBDF1 LPA INSR LPIN2 IGSF1 PLG	2.13e-05	541	57	8	MM1061
Coexpression	GSE9960_HEALTHY_VS_GRAM_NEG_AND_POS_SEPSIS_PBMC_UP	SUSD2 INSRR SPAG8 CFAP69 MUC6	5.43e-05	187	57	5	M7123
Coexpression	NABA_MATRISOME	TINAGL1 CRISPLD2 HGFAC LPA LAMC1 CDCP2 PLG MUC2 MUC6 OTOG	5.65e-05	1008	57	10	MM17056
Coexpression	NABA_ECM_GLYCOPROTEINS	TINAGL1 CRISPLD2 LAMC1 CDCP2 OTOG	6.00e-05	191	57	5	MM17059
Coexpression	NABA_MATRISOME	TINAGL1 CRISPLD2 HGFAC LPA LAMC1 CDCP2 PLG MUC2 MUC6 OTOG	6.55e-05	1026	57	10	M5889
Coexpression	NABA_ECM_GLYCOPROTEINS	TINAGL1 CRISPLD2 LAMC1 CDCP2 OTOG	6.78e-05	196	57	5	M3008
Coexpression	RANKIN_ANGIOGENIC_TARGETS_OF_VHL_HIF2A_UP	LPA PLG	6.93e-05	6	57	2	MM555
Coexpression	GSE11924_TH2_VS_TH17_CD4_TCELL_UP	MYO9A SCAMP5 LPIN2 IGSF1 TTLL13	7.29e-05	199	57	5	M3164
Coexpression	PILON_KLF1_TARGETS_UP	ABCC3 HGFAC RHBDF1 INSR LPIN2 IGSF1 PLG	1.06e-04	503	57	7	M2226
Coexpression	AIZARANI_LIVER_C7_EPCAM_POS_BILE_DUCT_CELLS_2	ABCC3 RHBDF1 LRP10 LAMC1 MUC6	1.14e-04	219	57	5	M39111
Coexpression	CAIRO_LIVER_DEVELOPMENT_DN	TMEM30B HGFAC LPA LPIN2 PLG	1.72e-04	239	57	5	MM1274
ToppCell	3'-Broncho-tracheal-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CRISPLD2 GXYLT2 NOX4 LAMC1 OVCH1	2.75e-06	172	57	5	e37c0b5b547a7345179ab258dd2141fec7064c17
ToppCell	facs-Lung-nan-3m-Mesenchymal-Alveolar_Fibroblast\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	LPIN3 CRISPLD2 MAS1 NOX4 LAMC1	3.62e-06	182	57	5	dbe4b2557cf19e0682ed446f8397d3a1153642f0
ToppCell	facs-Lung-nan-3m-Mesenchymal-fibroblast_of_lung\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	LPIN3 CRISPLD2 MAS1 NOX4 LAMC1	3.62e-06	182	57	5	c557de6ccd327c46e0a5423cd9936d78e0abae5f
ToppCell	5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-Adventitial_fibroblasts_L.2.1.2.2\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	LPIN3 CRISPLD2 GXYLT2 NOX4 IGSF1	3.72e-06	183	57	5	06a68fa2be36448064f4668be24a5b85ad85c6e8
ToppCell	facs-Liver-Hepatocytes-24m\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TMEM30B ABCC3 HGFAC NOX4 PLG	3.72e-06	183	57	5	d0721c6aa426953a520d40e976b6e65aa7ca65e8
ToppCell	facs-Thymus-nan-3m-Epithelial-epithelial_cell_of_thymus\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GXYLT2 NOX4 PLG CRB1	3.12e-05	140	57	4	115bd770a9d5e6f007a9aa0eadf5dba46d500107
ToppCell	facs-Thymus-nan-3m-Epithelial\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GXYLT2 NOX4 PLG CRB1	3.12e-05	140	57	4	22d126e80bf7d9c0ca6ec686b5cc66fa584a1ab6
ToppCell	facs-Thymus-nan-3m-Epithelial-TECs\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GXYLT2 NOX4 PLG CRB1	3.12e-05	140	57	4	62d1ef8cb78618ed89cac7ec89d7f54de06a90c7
ToppCell	390C-Lymphocytic-NK_cells-NK_cell_B0\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	RHBDF1 TMEM8B MAS1 RSPH10B	4.64e-05	155	57	4	a16e3a72badafa78a3efc4f4ab62396f0ce99d1e
ToppCell	390C-Lymphocytic-NK_cells-NK_cell_B0\|NK_cells / Donor, Lineage, Cell class and subclass (all cells)	RHBDF1 TMEM8B MAS1 RSPH10B	5.92e-05	165	57	4	ebd668e87e5961a124d1d6fc25d1f03e4af05cd4
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-4M-Radial_glial-RGCs_early_2\|Organoid-4M / Sample Type, Dataset, Time_group, and Cell type.	TINAGL1 RHBDF1 LRP10 INSRR	5.92e-05	165	57	4	e460e03992781073cd836a655f15dda3157cea55
ToppCell	RA-01._Fibroblast_I\|RA / Chamber and Cluster_Paper	CRISPLD2 INSRR NOX4 LAMC1	6.50e-05	169	57	4	6373562ab3b1765060212a6a53d6543e7e942e80
ToppCell	AT1-AT2_cells-Cryobiopsy_01\|World / lung cells shred on cell class, cell subclass, sample id	ABCC3 SUSD2 IGSF1 MUC6	6.96e-05	172	57	4	0be41df5d35d818deb7316ac21c9366eb4b7bfd1
ToppCell	Healthy/Control-pDC\|Healthy/Control / Disease group and Cell class	TINAGL1 GXYLT2 SCAMP5 TMEM8B	7.94e-05	178	57	4	072b346c6bbd63f00efaceda486400a669b3ec48
ToppCell	LA-01._Fibroblast_I\|LA / Chamber and Cluster_Paper	CRISPLD2 INSRR NOX4 LAMC1	8.12e-05	179	57	4	dcb6ec9ae72b13fe388b72dace2815293fafe8ee
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_3\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ABCC3 SUSD2 INSR PLG	8.84e-05	183	57	4	85446581999cd66b171c4f69b7eb8b0bbbaa8617
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_myocytic-mes_ASM_(13)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	TINAGL1 CRISPLD2 GADL1 LRP1B	1.02e-04	190	57	4	938d1f66094b1c94606e0d40213a39e5112f3322
ToppCell	facs-Heart-LV-3m-Mesenchymal\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CRISPLD2 RHBDF1 SUSD2 LAMC1	1.04e-04	191	57	4	b7a57691a4742070cee640e285c1f4d0da95baf1
ToppCell	LA\|World / Chamber and Cluster_Paper	CRISPLD2 NOX4 LAMC1 LRP1B	1.09e-04	193	57	4	d4bf89437216baf489ea0239136dcedf3b6714af
ToppCell	10x_3'_v2v3-Non-neoplastic-Endothelial-Endothelial_mature-Endo_arterial-A\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	TINAGL1 TMEM233 INSR NOX4	1.09e-04	193	57	4	3f8280ef849d95b2fcea5e6824b95a07febc96d0
ToppCell	5'-Adult-SmallIntestine-Mesenchymal-fibroblastic-mLN_Stroma_(FMO2+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CRISPLD2 NOX4 LAMC1 IGSF1	1.09e-04	193	57	4	7c0d84b92470bfda2db1e5007feee7c1235a0a78
ToppCell	facs-Lung-nan-3m-Mesenchymal\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CRISPLD2 GXYLT2 NOX4 LAMC1	1.09e-04	193	57	4	d9c20a092b507c43fcf7ccb04073fecd27d1749c
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-Adventitial_fibroblasts_L.2.1.2.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CRISPLD2 GXYLT2 NOX4 LAMC1	1.13e-04	195	57	4	f54bc4454270ff06e85596f98199372b50d0179f
ToppCell	Control_saline-Epithelial_airway-airway_epithelial-Ciliated\|Control_saline / Treatment groups by lineage, cell group, cell type	SPAG8 CFAP69 SOAT2 RSPH10B	1.13e-04	195	57	4	60067b5359174f0d1a8b5748bfc0690762e9e740
ToppCell	Globus_pallidus-Endothelial-ENDOTHELIAL_STALK-Flt1_2-Endothelial_Stalk.Flt1.Lcn2_(Vwf)\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	HGFAC MUC6 SOAT2	1.17e-04	74	57	3	0288a3f4eafbc359d01cde4ba58f946dd07c77cb
ToppCell	Globus_pallidus-Endothelial-ENDOTHELIAL_STALK-Flt1_2\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	HGFAC MUC6 SOAT2	1.17e-04	74	57	3	57884ade66fe39398351685189df5efd7aea0aab
ToppCell	Globus_pallidus-Endothelial-ENDOTHELIAL_STALK-Flt1_2-Endothelial_Stalk.Flt1.Lcn2_(Vwf)--\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	HGFAC MUC6 SOAT2	1.17e-04	74	57	3	13093139a75bfe11f6b032c9fb402efcc703551c
ToppCell	Globus_pallidus-Endothelial-ENDOTHELIAL_STALK-Flt1_2-Endothelial_Stalk.Flt1.Lcn2_(Vwf)-\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	HGFAC MUC6 SOAT2	1.17e-04	74	57	3	7f7de9e8142d2435391ee965cee5628e412f0705
ToppCell	10x_3'_v2v3-Non-neoplastic-Endothelial-Endothelial_immature\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	TINAGL1 TMEM233 INSR NOX4	1.17e-04	197	57	4	62c0a90869431e582bb7bb329e0b0cc59123d3d1
ToppCell	10x_3'_v2v3-Non-neoplastic-Endothelial-Endothelial_mature-Endo_arterial-G\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	TMEM233 INSR NOX4 LAMC1	1.17e-04	197	57	4	a312d9cf4ced949307eb9620be4eed926300b892
ToppCell	10x_3'_v2v3-Non-neoplastic-Endothelial-Endothelial_immature-Tip-like\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	TINAGL1 TMEM233 INSR NOX4	1.17e-04	197	57	4	16f0eb047df9d702518f82ee99c6e7dc1350b2fb
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Endothelial-Endothelial_mature-Endo_arterial-A\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	TINAGL1 INSR NOX4 LAMC1	1.17e-04	197	57	4	9244f087ba4b60fdc81d54ce91860de715b3e12c
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-Adventitial_fibroblasts_L.2.1.2.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CRISPLD2 GXYLT2 NOX4 LAMC1	1.17e-04	197	57	4	71786e9432e2d649f5d86f639abb25e7102deb67
ToppCell	10x_3'_v2v3-Non-neoplastic-Endothelial-Endothelial_immature-Tip-like-A\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	TINAGL1 TMEM233 INSR NOX4	1.17e-04	197	57	4	9e948b2e0f7e426f1e6f95bbbf4282fbddc2b99d
ToppCell	Tracheal-NucSeq-Epithelial-Epi_airway_ciliated-Deuterosomal\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	RSPH10B2 STIL SPAG8 RSPH10B	1.20e-04	198	57	4	f31790442ef142f1c0c49bf3daf2d0efb193d2c9
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Endothelial-Endothelial_mature-Endo_arterial\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	TINAGL1 INSR NOX4 LAMC1	1.20e-04	198	57	4	7cddd474416651088a4e08edfc0ac420ff10a5fe
ToppCell	3'-Broncho-tracheal-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-Adventitial_fibroblasts_L.2.1.2.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CRISPLD2 GXYLT2 NOX4 LAMC1	1.22e-04	199	57	4	1fd7bbb8727607e6507848602a19bc86882ef2d5
ToppCell	3'-Broncho-tracheal-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CRISPLD2 GXYLT2 NOX4 LAMC1	1.22e-04	199	57	4	9672230aa0bc6a7289050c955f5154ca183a5159
ToppCell	3'-Broncho-tracheal-Mesenchymal-Fibroblastic-fibroblastic_type_1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CRISPLD2 GXYLT2 NOX4 LAMC1	1.22e-04	199	57	4	e18abe678da293bd01fae55e2f9ab6fdd643d02d
ToppCell	10x_3'_v2v3-Non-neoplastic-Endothelial-Endothelial_mature-Endo_arterial-F\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	TMEM233 INSR NOX4 LAMC1	1.22e-04	199	57	4	463ba77dc4c85eebb343f29a42c7ac889b0497c9
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Endothelial-Endothelial_immature-Tip-like-F\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	TMEM233 INSR NOX4 LAMC1	1.22e-04	199	57	4	63c01e8961f48ed1bed4ab619cacf318cd6de7b9
ToppCell	cellseq2-Mesenchymal\|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	TINAGL1 CRISPLD2 SUSD2 LAMC1	1.24e-04	200	57	4	6b558cce0d6047c7e85f428adff80c5ca3084ea4
ToppCell	facs-Brain_Non-Myeloid-Hippocampus\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	WSCD1 LRP10 SCAMP5 LDAH	1.24e-04	200	57	4	fc28f71ca1cd0fdae66009ae5afe175d22f2bd8c
ToppCell	10x_3'_v2v3-Non-neoplastic-Endothelial\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	TINAGL1 TMEM233 INSR NOX4	1.24e-04	200	57	4	061ba851f941c616ddb462512e826c412881c3ce
Drug	probucol	LRP10 LPA NOX4 PLG LPAL2 LRP1B SOAT2	1.59e-07	162	57	7	CID000004912
Drug	PF-00562151-00 [351320-12-2]; Up 200; 10uM; MCF7; HT_HG-U133A	WSCD1 ABCC3 TMEM8B PLG SPAG8 CFAP69	8.96e-06	194	57	6	5954_UP
Drug	Aminocaproic Acid	LPA PLG	1.84e-05	3	57	2	DB00513
Drug	mangrove	LRP10 LPA INSR ALOXE3 PLG LPAL2 LRP1B SOAT2	2.05e-05	468	57	8	CID000000965
Drug	sodium linoleate	RHBDF1 LRP10 LPA ALOXE3 LPAL2 LRP1B SOAT2	2.25e-05	342	57	7	CID000003931
Drug	AC1L1J6H	ABCC3 LRP10 LPA LPAL2 LRP1B SOAT2	2.72e-05	236	57	6	CID000004889
Drug	ezetimibe	ABCC3 LRP10 LPA LRP1B SOAT2	3.35e-05	147	57	5	CID000150311
Disease	cholesteryl esters to total lipids in small LDL percentage	HGFAC LPA PLG LPAL2 SOAT2	1.65e-08	42	56	5	EFO_0022255
Disease	lipoprotein A measurement, apolipoprotein A 1 measurement	LPA PLG LPAL2	2.25e-07	7	56	3	EFO_0004614, EFO_0006925
Disease	lipoprotein A measurement	MAS1 LPA PLG LPAL2 SOAT2	2.36e-06	112	56	5	EFO_0006925
Disease	free cholesterol to total lipids in large HDL percentage	HGFAC LPA PLG LPAL2	3.97e-06	56	56	4	EFO_0022279
Disease	low density lipoprotein particle size measurement	LPA PLG LPAL2 SOAT2	4.57e-06	58	56	4	EFO_0008593
Disease	very low density lipoprotein particle size measurement	HGFAC LPA INSR PLG LPAL2	5.48e-06	133	56	5	EFO_0008594
Disease	triglycerides in small VLDL measurement	HGFAC LPA PLG LPAL2	5.60e-06	61	56	4	EFO_0022145
Disease	triglycerides to total lipids in very large HDL percentage	HGFAC LPA PLG LPAL2	5.98e-06	62	56	4	EFO_0022339
Disease	triglycerides in small HDL measurement	HGFAC LPA PLG LPAL2	5.98e-06	62	56	4	EFO_0022158
Disease	phospholipids in large VLDL measurement	HGFAC LPA PLG LPAL2	5.98e-06	62	56	4	EFO_0022169
Disease	free cholesterol in very large HDL measurement	HGFAC LPA PLG LPAL2	5.98e-06	62	56	4	EFO_0022273
Disease	free cholesterol to total lipids in medium LDL percentage	HGFAC LPA PLG LPAL2	6.38e-06	63	56	4	EFO_0022283
Disease	triglycerides in small LDL measurement	HGFAC LPA PLG LPAL2	7.23e-06	65	56	4	EFO_0022323
Disease	total lipids in very large HDL measurement	HGFAC LPA PLG LPAL2	7.68e-06	66	56	4	EFO_0022312
Disease	phospholipids in very large HDL measurement	HGFAC LPA PLG LPAL2	7.68e-06	66	56	4	EFO_0022298
Disease	triglycerides to phosphoglycerides ratio	HGFAC LPA PLG LPAL2	8.65e-06	68	56	4	EFO_0022327
Disease	free cholesterol in large VLDL measurement	HGFAC LPA PLG LPAL2	8.65e-06	68	56	4	EFO_0022265
Disease	triglycerides to total lipids in very small VLDL percentage	HGFAC LPA PLG LPAL2	9.17e-06	69	56	4	EFO_0022341
Disease	cholesterol in very large HDL measurement	HGFAC LPA PLG LPAL2	9.17e-06	69	56	4	EFO_0022229
Disease	myoglobinuria (implicated_via_orthology)	LPIN3 LPIN2	1.06e-05	3	56	2	DOID:0080108 (implicated_via_orthology)
Disease	low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio	HGFAC LPA PLG LPAL2 SOAT2	1.08e-05	153	56	5	EFO_0004611, EFO_0020946
Disease	low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio	HGFAC LPA PLG LPAL2 SOAT2	1.08e-05	153	56	5	EFO_0004611, EFO_0020944
Disease	free cholesterol to total lipids in large LDL percentage	HGFAC LPA PLG LPAL2	1.21e-05	74	56	4	EFO_0022280
Disease	monounsaturated fatty acids; 16:1, 18:1 measurement	HGFAC LPA PLG LPAL2	1.49e-05	78	56	4	EFO_0022187
Disease	chylomicron measurement, very low density lipoprotein cholesterol measurement, lipid measurement	HGFAC LPA PLG LPAL2	3.26e-05	95	56	4	EFO_0004529, EFO_0008317, EFO_0008596
Disease	chylomicron measurement, triglyceride measurement, very low density lipoprotein cholesterol measurement	HGFAC LPA PLG LPAL2	3.39e-05	96	56	4	EFO_0004530, EFO_0008317, EFO_0008596
Disease	chronic kidney disease, APOL1 risk genotype carrier status	LPA PLG	3.52e-05	5	56	2	EFO_0003884, EFO_0009324
Disease	plasma plasminogen measurement	LPA PLG	3.52e-05	5	56	2	EFO_0006309
Disease	mucinous adenocarcinoma (is_marker_for)	MUC2 MUC6	3.52e-05	5	56	2	DOID:3030 (is_marker_for)
Disease	chylomicron measurement, very low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio	LPA PLG LPAL2	3.72e-05	34	56	3	EFO_0008317, EFO_0008596, EFO_0020944
Disease	chylomicron measurement, triglycerides:total lipids ratio, very low density lipoprotein cholesterol measurement	LPA PLG LPAL2	3.72e-05	34	56	3	EFO_0008317, EFO_0008596, EFO_0020947
Disease	triglyceride measurement, alcohol drinking	HGFAC LPA INSR PLG	3.83e-05	99	56	4	EFO_0004329, EFO_0004530
Disease	triglyceride measurement, alcohol consumption measurement	HGFAC LPA INSR PLG	4.14e-05	101	56	4	EFO_0004530, EFO_0007878
Disease	cholesteryl esters to total lipids in medium LDL percentage	HGFAC LPA PLG	4.81e-05	37	56	3	EFO_0022252
Disease	chylomicron measurement, very low density lipoprotein cholesterol measurement	HGFAC LPA PLG LPAL2	5.00e-05	106	56	4	EFO_0008317, EFO_0008596
Disease	angiostatin measurement	LPA PLG	5.28e-05	6	56	2	EFO_0008024
Disease	chylomicron measurement, very low density lipoprotein cholesterol measurement, phospholipid measurement	HGFAC LPA PLG LPAL2	5.58e-05	109	56	4	EFO_0004639, EFO_0008317, EFO_0008596
Disease	aspirin use measurement	PCNX3 LPA LPAL2	5.64e-05	39	56	3	EFO_0007013
Disease	cholesteryl ester measurement, chylomicron measurement, very low density lipoprotein cholesterol measurement	HGFAC LPA PLG LPAL2	5.78e-05	110	56	4	EFO_0008317, EFO_0008596, EFO_0010351
Disease	free cholesterol measurement, chylomicron measurement, very low density lipoprotein cholesterol measurement	HGFAC LPA PLG LPAL2	5.78e-05	110	56	4	EFO_0008317, EFO_0008591, EFO_0008596
Disease	chylomicron measurement, total cholesterol measurement, very low density lipoprotein cholesterol measurement	HGFAC LPA PLG LPAL2	5.78e-05	110	56	4	EFO_0004574, EFO_0008317, EFO_0008596
Disease	very low density lipoprotein cholesterol measurement, lipid measurement	HGFAC LPA INSR PLG LPAL2	6.17e-05	220	56	5	EFO_0004529, EFO_0008317
Disease	very low density lipoprotein cholesterol measurement, cholesterol:total lipids ratio	HGFAC LPA INSR PLG LPAL2	6.44e-05	222	56	5	EFO_0008317, EFO_0020943
Disease	triglyceride measurement, very low density lipoprotein cholesterol measurement	HGFAC LPA INSR PLG LPAL2	6.72e-05	224	56	5	EFO_0004530, EFO_0008317
Disease	phospholipids:total lipids ratio	HGFAC LPA PLG LPAL2 SOAT2	7.16e-05	227	56	5	EFO_0020946
Disease	high grade glioma (implicated_via_orthology)	ATG7 INSR INSRR	8.11e-05	44	56	3	DOID:3070 (implicated_via_orthology)
Disease	chylomicron measurement, very low density lipoprotein cholesterol measurement, cholesterol:total lipids ratio	LPA PLG LPAL2	9.28e-05	46	56	3	EFO_0008317, EFO_0008596, EFO_0020943
Disease	polyunsaturated fatty acids to total fatty acids percentage	LPA PLG LPAL2	1.19e-04	50	56	3	EFO_0022303
Disease	alcohol dependence (implicated_via_orthology)	INSR INSRR	1.26e-04	9	56	2	DOID:0050741 (implicated_via_orthology)
Disease	polyunsaturated fatty acids to monounsaturated fatty acids ratio	LPA PLG LPAL2	1.26e-04	51	56	3	EFO_0022302
Disease	cholesterol to total lipids in small HDL percentage	LPA PLG LPAL2	1.26e-04	51	56	3	EFO_0022240
Disease	very low density lipoprotein cholesterol measurement	HGFAC LPA INSR PLG LPAL2	1.35e-04	260	56	5	EFO_0008317
Disease	triglycerides in HDL measurement	LPA PLG LPAL2	1.42e-04	53	56	3	EFO_0022317
Disease	free cholesterol to total lipids in small LDL percentage	LPA PLG LPAL2	1.42e-04	53	56	3	EFO_0022286
Disease	triglycerides in medium HDL measurement	LPA PLG LPAL2	1.50e-04	54	56	3	EFO_0022321
Disease	triglycerides in medium VLDL measurement	HGFAC LPA LPAL2	1.58e-04	55	56	3	EFO_0022155
Disease	cholesterol:total lipids ratio, low density lipoprotein cholesterol measurement	HGFAC LPA PLG SOAT2	1.64e-04	144	56	4	EFO_0004611, EFO_0020943
Disease	triglycerides in LDL measurement	HGFAC LPA PLG	1.67e-04	56	56	3	EFO_0022320
Disease	triglycerides in very large VLDL measurement	HGFAC LPA LPAL2	1.67e-04	56	56	3	EFO_0022325
Disease	triglycerides to total lipids in medium HDL percentage	LPA PLG LPAL2	1.67e-04	56	56	3	EFO_0022333
Disease	triglycerides in large VLDL measurement	HGFAC LPA LPAL2	1.67e-04	56	56	3	EFO_0022178
Disease	cholesteryl esters to total lipids in medium HDL percentage	LPA PLG LPAL2	1.67e-04	56	56	3	EFO_0022251
Disease	triglyceride measurement, phospholipid measurement	HGFAC LPA PLG LPAL2	1.73e-04	146	56	4	EFO_0004530, EFO_0004639
Disease	sleep disorder (implicated_via_orthology)	INSR INSRR	1.92e-04	11	56	2	DOID:535 (implicated_via_orthology)
Disease	triglycerides in VLDL measurement	HGFAC LPA LPAL2	1.95e-04	59	56	3	EFO_0022326
Disease	triglycerides to total lipids in small LDL percentage	LPA PLG LPAL2	1.95e-04	59	56	3	EFO_0022337
Disease	concentration of chylomicrons and extremely large VLDL particles measurement	HGFAC LPA LPAL2	1.95e-04	59	56	3	EFO_0022260
Disease	autism spectrum disorder (implicated_via_orthology)	SCAMP5 SCAMP1 LAMC1 SCAMP2	2.02e-04	152	56	4	DOID:0060041 (implicated_via_orthology)
Disease	triglycerides to total lipids in large HDL percentage	LPA PLG LPAL2	2.05e-04	60	56	3	EFO_0022330
Disease	cholesterol in chylomicrons and extremely large VLDL measurement	HGFAC LPA LPAL2	2.05e-04	60	56	3	EFO_0021898
Disease	total lipids in VLDL measurement	HGFAC LPA LPAL2	2.05e-04	60	56	3	EFO_0022314
Disease	cholesterol to total lipids in medium HDL percentage	LPA PLG LPAL2	2.05e-04	60	56	3	EFO_0022237
Disease	free cholesterol in very large VLDL measurement	HGFAC LPA LPAL2	2.16e-04	61	56	3	EFO_0022274
Disease	chylomicron measurement, very low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio	HGFAC LPA PLG	2.16e-04	61	56	3	EFO_0008317, EFO_0008596, EFO_0020946
Disease	triglycerides in medium LDL measurement	HGFAC LPA PLG	2.26e-04	62	56	3	EFO_0022322
Disease	total lipids in chylomicrons and extremely large VLDL measurement	HGFAC LPA LPAL2	2.26e-04	62	56	3	EFO_0022306
Disease	total lipids in very large VLDL measurement	HGFAC LPA LPAL2	2.26e-04	62	56	3	EFO_0022313
Disease	free cholesterol in chylomicrons and extremely large VLDL measurement	HGFAC LPA LPAL2	2.26e-04	62	56	3	EFO_0022263
Disease	phospholipids in very large VLDL measurement	HGFAC LPA LPAL2	2.26e-04	62	56	3	EFO_0022299
Disease	triglycerides to total lipids in medium VLDL percentage	LPA PLG LPAL2	2.37e-04	63	56	3	EFO_0022335
Disease	cholesterol to total lipids in medium VLDL percentage	LPA PLG LPAL2	2.37e-04	63	56	3	EFO_0022239
Disease	phospholipids in chylomicrons and extremely large VLDL measurement	HGFAC LPA LPAL2	2.37e-04	63	56	3	EFO_0022292
Disease	cholesteryl esters to total lipids in medium VLDL percentage	LPA PLG LPAL2	2.49e-04	64	56	3	EFO_0022253
Disease	cholesterol in very large VLDL measurement	HGFAC LPA LPAL2	2.60e-04	65	56	3	EFO_0022230
Disease	triglyceride measurement, low density lipoprotein cholesterol measurement	HGFAC LPA PLG LPAL2	2.82e-04	166	56	4	EFO_0004530, EFO_0004611
Disease	total lipids in large VLDL	HGFAC LPA LPAL2	2.85e-04	67	56	3	EFO_0022175
Disease	cholesterol to total lipids in very small VLDL percentage	LPA PLG LPAL2	2.85e-04	67	56	3	EFO_0022245
Disease	Abdominal Aortic Aneurysm	CRISPLD2 LPA LDAH	2.97e-04	68	56	3	EFO_0004214
Disease	high density lipoprotein particle size measurement	HGFAC LPA PLG LPAL2	3.09e-04	170	56	4	EFO_0008592
Disease	diabetic neuropathy (implicated_via_orthology)	INSR INSRR	3.17e-04	14	56	2	DOID:9743 (implicated_via_orthology)
Disease	cholesteryl esters to total lipids in very small VLDL percentage	HGFAC LPA LPAL2	3.38e-04	71	56	3	EFO_0022259
Disease	triglycerides to total lipids in small HDL percentage	LPA PLG LPAL2	3.52e-04	72	56	3	EFO_0022336
Disease	triglycerides to total lipids in chylomicrons and extremely large VLDL percentage	LPA LPAL2	3.66e-04	15	56	2	EFO_0022328
Disease	lipid metabolism disorder (implicated_via_orthology)	LPIN3 LPIN2	3.66e-04	15	56	2	DOID:3146 (implicated_via_orthology)
Disease	free cholesterol to total lipids in small VLDL percentage	LPA PLG LPAL2	3.97e-04	75	56	3	EFO_0022287
Disease	pre-malignant neoplasm (biomarker_via_orthology)	INSR MUC2	4.72e-04	17	56	2	DOID:0060071 (biomarker_via_orthology)
Disease	cholesterol to total lipids in chylomicrons and extremely large VLDL percentage	LPA LPAL2	4.72e-04	17	56	2	EFO_0022232
Disease	omega-6 polyunsaturated fatty acid measurement	HGFAC LPA PLG LPAL2	5.40e-04	197	56	4	EFO_0005680
Disease	low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio	HGFAC LPA PLG LPAL2	5.71e-04	200	56	4	EFO_0004611, EFO_0020945
Disease	triglycerides:total lipids ratio, high density lipoprotein cholesterol measurement	HGFAC LPA PLG LPAL2	6.38e-04	206	56	4	EFO_0004612, EFO_0020947

Protein segments in the cluster

Peptide	Gene	Start	Entry
FPRLYPYNTECSWLI	CDCP2	46	Q5VXM1
PCIYLWVALPCYLLY	ABCC3	41	O15438
CWEIYLAYCRPSAAP	RSPH10B	556	P0C881
CWEIYLAYCRPSAAP	RSPH10B2	556	B2RC85
WRTPAFCPIYCGFYN	MUC6	1121	Q6W4X9
EYSNFCYWREPLPAV	LPIN3	831	Q9BQK8
TYHVRGYCLPWDRPC	LRP10	301	Q7Z4F1
SLDPQAGYLYWIDCC	LRP1B	3136	Q9NZR2
CLSVLYPIWYRCHRP	MAS1	131	P04201
QECYRWKIYAPGFPC	ALOXE3	141	Q9BYJ1
VDWTYDPNEPRYCIC	ING3	351	Q9NXR8
NWVIAYSRPVYFCIC	PCNX3	851	Q9H6A9
WRTPDLCPIFCDYYN	MUC2	1111	Q02817
KDYTYPYPSECNPWC	CRISPLD2	136	Q9H0B8
ECLYVFPCQWNYRPD	GXYLT2	326	A0PJZ3
ETCPPPYYHFQDWRC	INSR	266	P06213
AYCRNPDNDERPWCY	HGFAC	336	Q04756
YYDGWLICEEPTCRN	POLA1	1341	P09884
WISGPLCLYCAERLY	NOX4	286	Q9NPH5
CSYRLQAYPDIWSEP	IGSF1	1226	Q8N6C5
YWFCYPALCLPESLP	ATG7	146	O95352
YRCSRWPCPNVVDCF	GJA8	181	P48165
NCYSNYPFPLTSWPC	GCM1	311	Q9NP62
PCSCAWYFSLPELFQ	TMEM30B	91	Q3MIR4
PYCYTRDPGVRWEYC	LPA	86	P08519
PYCYTRDPGVRWEYC	LPA	656	P08519
CYTRDPSVRWEYCNL	LPA	886	P08519
NYCRNPDAEIRPWCY	LPA	1101	P08519
YCRNPDAEISPWCYT	LPA	1216	P08519
NYCRNPDAEIRPWCY	LPA	1321	P08519
YCRNPDAEIRPWCYT	LPA	1436	P08519
ACPPGTYQYESWRCV	INSRR	261	P14616
DAYECLDASRPWLCY	FNTB	91	P49356
YNRSWPGCQECPACY	LAMC1	1021	P11047
EYANICFWYIPPSLR	GADL1	436	Q6ZQY3
AYLYEERWTPPCCLR	FKRP	306	Q9H9S5
WLSYQCDCHRPYEGP	CRB1	691	P82279
IWCCILGCYPSEDYF	CFAP69	591	A5D8W1
FTPCSYVCWFRPIYK	SCAMP5	81	Q8TAC9
VDWRTPRLCPYDCDF	OTOG	1231	Q6ZRI0
YPICEWRYDACASPC	OTOG	1406	Q6ZRI0
YICYICRDPPGQRWS	PHF20L1	721	A8MW92
FYYCCLWAPDCPRYM	SUSD2	416	Q9UGT4
IYPVLGTYWDNCNRC	TINAGL1	111	Q9GZM7
NYLWLTIVSCFCPAY	TMEM233	36	B4DJY2
CYETLPRGQCLLYNW	SPAG8	271	Q99932
LLSYFPSPYQRWICC	BMT2	246	Q1RMZ1
YCRNPDCSAGPWCYT	LPAL2	76	Q16609
YPDLYPSNIRCHWFI	OVCH1	436	Q7RTY7
LFYVYPVRCEWCEFL	RHBDF1	821	Q96CC6
FLLFTPCSFVCWYRP	SCAMP1	191	O15126
PCSFVCWYRPLYGAF	SCAMP1	196	O15126
FLIFTPCAFLCWYRP	SCAMP2	191	O15127
PCAFLCWYRPIYKAF	SCAMP2	196	O15127
RETEQCWVQPPYKYC	WFDC9	36	Q8NEX5
PWCYTTNPRKLYDYC	PLG	541	P00747
LYCQEWYARRHCPLP	SOAT2	491	O75908
WNCCFIPLRLVFPYQ	CNGB3	231	Q9NQW8
YSPQVWACCLRYIFN	STIL	271	Q15468
CYPPTWRRWLFYLCP	TMEM8B	371	A6NDV4
PYRCPWCDYRSNCAE	ZNF407	1741	Q9C0G0
PLAILRGWECYCAYP	WSCD1	286	Q658N2
RGWECYCAYPTPRFN	WSCD1	291	Q658N2
LYPSEYNIFPRTWCL	TTLL13	166	A6NNM8
CQPCTESPELYDWLY	JKAMP	46	Q9P055
CKLTFYYGTIDPWCP	LDAH	261	Q9H6V9
AFPCPEFSSFCYWRD	LPIN2	871	Q92539
PLRQSWDDYCYDSEP	MYO9A	371	B2RTY4